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Background: With increasing numbers of type 2 diabetes (DM2) and hypertension patients, there is a pressing
need for effective, time-efficient and sustainable strategies to help physicians support their patients to achieve
higher physical activity levels. SMARTER will determine whether physician-delivered step count prescriptions reduce
arterial stiffness over a one-year period, compared with usual care, in sedentary overweight/obese adults with
DM2/hypertension.
Design: Randomized, allocation-concealed, assessor-blind, multisite clinical trial. The primary outcome is change in
arterial stiffness over one year. The secondary outcomes include changes in physical activity, individual vascular risk
factors, medication use, and anthropometric parameters. Assessments are at baseline and one year.
Methods: Participants are sedentary/low active adults with 25≤ BMI < 40 kg/m2 followed for DM2/hypertension by
a collaborating physician. The active arm uses pedometers to track daily step counts and review logs with their
physicians at 3 to 4-month intervals. A written step count prescription is provided at each visit, aiming to increase
counts by ≥3,000 steps/day over one year, with an individualized rate increase. The control arm visits physicians at
the same frequency and receives advice to engage in physical activity 30-60 minutes/day. SMARTER will enroll 364
individuals to detect a 10 ± 5% difference in arterial stiffness change between arms. Arterial stiffness is assessed
noninvasively with carotid femoral pulse wave velocity using applanation tonometry.
Discussion: The importance of SMARTER lies not simply in the use of pedometer-based monitoring but also on its
integration into a prescription-based intervention delivered by the treating physician. Equally important is the
measurement of impact of this approach on a summative indicator of arterial health, arterial stiffness. If effectiveness
is demonstrated, this strategy has strong potential for widespread uptake and implementation, given that it is
well-aligned with the structure of current clinical practice.
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Longitudinal studies have demonstrated the protective
effects of higher walking levels on arterial health in
adults with type 2 diabetes (DM2) and hypertension. In
the National Health Interview Survey [1], walking 120
minutes or more each week resulted in a 40% relative
mortality rate reduction over 12 years. In the Nurses’
Health Study [2], those in the highest quartile of walking
lowered their risk of heart attack, stroke, and related
mortality by more than 30% over a decade. However,
walking levels have declined in an era of Internet tran-
sactions, ‘smart’ phones, and ‘social networking,’ contri-
buting to escalating rates of obesity and its detrimental
consequences [3-7].
A meta-analysis indicates that the integration of physical
activity promotion into primary care is associated with a
42% increase in self-reported activity [8]. The Green Pres-
cription approach (physical activity-based prescriptions with
three telephone-based support calls from trained coun-
selors) has been widely implemented in the primary care
context in New Zealand and has demonstrated sustained
increases in physical activity levels [9]. These approaches,
however, require paramedical staff support which may not
be feasible in many settings. A more physician-driven ap-
proach had some effect on physical activity levels [10], but
physicians generally lack the skills or time to provide more
complex physical activity counseling, despite calls for more
specific prescriptions [11]. In this regard, step count moni-
tors such as pedometers may be a useful tool.
Pedometers permit simple, real-time tracking of walk-
ing and other step-related activity. Among NAVIGA-
TOR trial participants (Nateglinide and Valsartan in
Impaired Glucose Tolerance Outcomes Research [12]),
both pedometer-assessed daily step counts at baseline
(hazard ratio [HR] per 2,000 steps/day 0.90, 95% CI
0.84–0.96) and change in step counts over an average
follow-up of 6 years (HR per 2,000 steps/day increase
0.92, 95% CI 0.86–0.99) led to reductions in cardiovas-
cular disease events. These effects were independent of
one another and also independent of underlying co-
morbidities and changes in body mass index (BMI).
Group pedometer-based programs increase physical ac-
tivity levels and improve vascular risk profiles. In a
meta-analysis of eight clinical trials [13], such interven-
tions led to a 2,491 daily step increase [95% Confidence
Interval (CI) 1,098 to 3,885], a -3.8 mm Hg change in sys-
tolic blood pressure (95% CI -5.9 to -1.7) and a -0.38 kg/
m2 change in BMI (95% CI -0.05 to -0.72). These pro-
grams, however, may not be available or sustainable. Self-
monitoring and target setting could be an inexpensive and
accessible option, with assistance through web-based tools,
but for many individuals this may not provide sufficient ac-
countability and motivational support, elements deemed
important to change health behaviours [14].Integration of pedometer-based monitoring into routine
medical visits, however, could help meet the need for
accountability and support, without requiring additional
staffing. We have developed such a strategy and we are
testing it through a randomized controlled trial, as des-
cribed herein. In our strategy, participants self-monitor
and track step counts. They review these records with
their physicians who then assist them in setting realistic
step count targets, consistent with the monitoring-prescrip-
tion-monitoring-adjusted prescription dynamic approach to
which both physicians and patients are accustomed. Many
patients with DM2 and hypertension self-monitor glucose
and blood pressure levels; based on this information, their
physicians are better-positioned to prescribe and adjust
medications [15]. Such a strategy has not previously been
evaluated for physical activity monitoring. A recent Green
Prescription trial [16] integrated pedometer-based self-
monitoring in a clinic setting and demonstrated higher
activity levels, but again the intervention structure relied
on paramedical clinic staff, rather than being routinely
integrated as a component of medical visits with a phy-
sician. Thus the physician-patient relationship, an impor-
tant factor in adherence to medications and physical
activity, [17,18] was a less important factor in the inter-
vention. In contrast, this is arguably the most important
element of the SMARTER strategy. Another trial [19] did
examine a physician-delivered intervention in DM2 and
demonstrated a step count increase over a 12-week period
but did not examine vascular effects; we are evaluating a
one-year physician-delivered intervention and its impact
on a summative indicator of arterial health, arterial stiff-
ness, as described below.
The previously-cited meta-analysis of group-based
pedometer interventions demonstrated reductions in
blood pressure [13]. While blood pressure is one im-
portant indicator of arterial health, recent technological
developments have allowed for a more comprehensive
assessment of the arterial system through measurement
of arterial stiffness, capturing the summative impact of
vascular risk factors. Epidemiological studies have demon-
strated that higher arterial stiffness is associated with
increased risk of vascular disease and events [20-24]. In a
trial among DM2 patients, a three-month supervised exer-
cise program conferred a 20% greater reduction in arterial
stiffness compared to usual care alone [25]. Higher daily
step counts have been associated with lower carotid
femoral pulse wave velocity (cfPWV), the gold standard
measure of arterial stiffness [26,27].
We are conducting a randomized controlled trial to
examine the effect of a physician-delivered step count
prescriptions on arterial stiffness in sedentary over-
weight/obese adults with DM2 and/or hypertension. We
present herein the design and methods of the SMARTER
(Step Monitoring to improve ARTERial health) trial.
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intervention on cfPWV using applanation tonometry.
Our secondary objectives are to assess effects on indivi-
dual vascular risk factors, medication use, anthropome-
tric parameters, and physical activity, as detailed below.
Methods
The SMARTER trial is registered at ClinicalTrials.gov
(NCT01475201). Funding is through the Canadian Insti-
tutes of Health Research (MOPP 114996). Approval of the
research protocol has been granted by McGill University’s
Faculty of Medicine Institutional Review Board and all par-
ticipating institutions (McGill University Health Centre,
St. Mary’s Hospital, Sir Mortimer General Jewish General
Hospital). Written informed consent is provided by all
participants.
Study design
SMARTER is a prospective, randomized, open-label,
blinded-endpoint (PROBE) trial comparing two stra-
tegies to increase physical activity among overweight/
obese adults followed for DM2 and/or hypertension.
Allocation is concealed with an intervention to alloca-
tion ratio of 1:1.
Eligibility criteria and recruitment
Inclusion criteria include physician-diagnosis of DM2 or
hypertension, age ≥18 years, and 25 kg/m2 ≤ BMI < 40
kg/m2 to permit accurate pedometer measurement [28].
Exclusion criteria include ≥ 150 minutes of leisure time
physical activity per week (i.e., fulfilling physical activity
recommendations) [29], co-morbid conditions with poten-
tial to affect adherence to trial procedures (e.g. inflamma-
tory arthritis, active malignancy, major depression or
other significant psychiatric disorders, and/or significant
visual impairment), and pregnancy/planning a pregnancy.
Further, following baseline evaluation but prior to ran-
domization, those with a baseline step count avera-
ging >10,000 steps/day (i.e., active) [30] are excluded.
Treating physicians are free to modify medications during
the trial period in both arms. Collaborating physicians are
based at family medicine, internal medicine, endocrino-
logy, and hypertension clinics in Montréal, Canada. They
identify potentially eligible participants during routine
clinic visits and obtain assent for contact by SMARTER
personnel.
Measurements
All measurements detailed below are assessed both at
baseline and following the intervention at one year so that
changes during the trial may be computed. These evalua-
tions are conducted at our Vascular Health Unit (Division
of Internal Medicine, McGill University Health Centre).Arterial stiffness
To avoid circadian variations that may affect arterial stiff-
ness measurements, we evaluate all participants in the
morning at approximately the same time of the day at
baseline and again at the final evaluation. Participants are
instructed to abstain from: i) caffeine and ethanol intake
for at least 12 hours and flavonoid-containing foods (such
as berries, grapes, apples, green tea, chocolate, nuts, herbs,
and spices) for at least 24 hours before the evaluation, ii)
any strenuous exercise (aerobic or anaerobic) for 24 hours
before the evaluation, and iii) exposure to cigarette smoke
for at least 12 hours before the evaluation. The partici-
pants are instructed to take all their medications except
their antihyperglycemic medications in the morning of the
baseline and final evaluations. Participants are requested
to fast overnight (12 hours) prior to evaluation.
CfPWV is measured using applanation tonometry
through the SphygmoCor system [31-34]. A high-fidelity
micromanometer is placed on the tip of a hand-held ton-
ometer (SPC-301; Millar Instruments, Houston, TX, USA)
and applied to the skin overlying the radial artery to flat-
ten but not occlude the artery. Using a previously vali-
dated generalized transfer function, the system software
calculates an averaged radial artery waveform and derives
a corresponding central pressure and other indices of
pulse wave analysis, including the augmentation index and
augmentation pressure [31,32,35,36]. The tonometer is
then applied over the carotid and subsequently the fe-
moral arteries with concurrent 3-lead ECG monitoring;
the PWV is automatically calculated from measurements
of the pulse transit time and the distance between the
carotid and femoral recording sites [PWV = distance (m)/
transit time (s)].
Physical activity
Participants are provided with two pedometers (Yamax
SW-701; viewing windows concealed) to assess step counts
and an accelerometer (Actiwatch-2; Phillips, Respironics)
to capture duration, frequency, and intensity of physical
activity. Participants wear one pedometer and the accele-
rometer for one week and then mail these to the study
centre with the unused pedometer (padded, pre-addressed,
pre-stamped envelope). The unused pedometer captures
the “postman steps” that occur during the mailing process
[37-39]; these are subtracted from the step counts re-
corded on the pedometer that is worn. Steps/day are com-
puted from this corrected value.
Physical fitness
Cardiorespiratory fitness is assessed through a supervised
maximal incremental test to determine VO2max (model
VMax229LV, Sensorsmedics, Yorba Linda, CA, USA) with
treadmill testing (MedTrackCR60 Treadmill, Quinton,
Bothell, WA, USA; Bruce ramp protocol).
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Weight and height are assessed to the nearest 0.1 kg
(SECA 882 electronic scale, light clothing, shoes re-
moved) and 0.1 cm (stadiometer), respectively. BMI is
calculated by dividing the weight in kilograms by height
in metres squared. Waist circumference is measured
midway between the iliac crest and the lower rib margin.
Hip circumference is measured at the point of greatest
posterior extension of the buttocks.
Blood pressure
Resting blood pressure is measured using the BpTRU Blood
Pressure Monitor using a standardized protocol [40].
Serum biomarkers
Lipid profile Total cholesterol, high density lipoprotein
cholesterol (HDL-C), and triglyceride levels are measured
using spectrophotometry and low density lipoprotein chol-
esterol (LDL-C) is calculated (Friedewald equation). Apoli-
poproteins A1 and B are measured using the turbimetric
method. In participants with DM2, hemoglobin A1C is
measured with a high-performance liquid chromatography
(HPLC) analyzer [41]. In those without DM2, fasting glu-
cose and insulin levels are measured and the Homeostatic
Model Assessment is calculated [(fasting insulin in μunits/
ml X fasting glucose in mmol/L) ÷ 22.5] [42-47]. High sen-
sitivity C-reactive protein is assayed through an immunone-
phelometric method.
Cardioprotective medications
Use of antihypertensive, antihyperglycemic, and lipid-
lowering medications (number and dose) is recorded.
Adherence
We are tracking clinic visits completed, prescriptions
written by collaborating physicians, and use of the step
count log book.
Randomization
Patient inclusion and data entry forms (eCFRs) were cre-
ated using web Electronic Data Capture software platform
from Dacima™. Data are entered through a web browser
into a web database that complies with regulatory require-
ments (FDA 21 CFR Part 11). First, data from the initial
telephone-based eligibility screen are entered on the elec-
tronic eligibility check web form. The EDC system verifies
the candidates’ responses to make a preliminary determin-
ation of eligibility. Candidates who fulfill preliminary as-
sessments for eligibility present in person for informed
consent procedures and baseline assessment. The baseline
evaluation is considered completed once the pedometers
with concealed viewing windows are received by study
personnel (see Measurements, Physical activity). Pedo-
meter-based step count data are entered into the webform. Those with more than 10,000 steps/day are deter-
mined to be ineligible by the EDC inclusion algorithm and
marked as excluded.
Eligible individuals are randomized to either the control
or the active trial arm through the Dacima™ Clinical soft-
ware (i.e., individual-level randomization with no stra-
tification; random permuted blocks with randomly-varied
block sizes of two, four and six).
Interventions
Participants are followed by their physician at 3 to
4-month intervals over 12 months. The control arm re-
ceives advice to engage in 30-60 minutes of activity daily,
consistent with usual care [48]. In the active arm, the
physician writes a step count prescription at each visit.
As previously noted, pedometer-based interventions led
to a 2,491 daily step increase in a meta-analysis [13]. A
step count increment of 2,500 to 3,000 steps is roughly
equivalent to 30 minutes of walking at a moderate pace,
as established through direct counts of individuals walk-
ing on a treadmill at a workload of 3 metabolic equiva-
lents (METS)/minute [49]. In the SMARTER active arm,
the aim is to achieve a net increase over baseline values
of at least 3,000 steps/day over one year. DM2 and
hypertension follow-up visits are recommended at 3 to 4
month intervals. Testing an intervention over 1 year per-
mits 3 to 4 contacts with the treating physician but still
respects the reality of usual clinical follow-up. This is
important if the results of this trial are to be imple-
mented in real-world practice following the trial itself. A
1-year study duration will mean that participants are
examined at roughly the same time of year (i.e., season)
at the baseline and final assessments. This will help en-
sure that any changes demonstrated are not attributable
to seasonal differences [50]. Finally, many physical acti-
vity intervention studies have been criticized as being
too short in duration; we suggest that a 1-year period of
intervention and follow-up provides a reasonable time
frame over which to evaluate effects.
The rapidity at which this is achieved is individually-
tailored (Figure 1). The baseline step count value is pro-
vided by the research team as derived from the baseline
assessment. The general time frame for the increase by
3,000 steps/day is 10 months for sedentary participants
(<5,000 steps/day), 7 months for low active participants
(5,000-7,499 steps/day), and 5 months for somewhat ac-
tive participants (7,500-9,999 steps/day). Subsequent
prescriptions are based on step counts achieved and in-
dividual circumstances.
Sample size
Madden and colleagues [25] conducted a randomized con-
trolled trial comparing a 3-month supervised exercise pro-
gram with usual care in adults with DM2, hypertension,
Figure 1 Step count prescription framework by baseline activity category. Months in red are those at which a clinic visit occurs. All
participants should ultimately achieve a net increase of at least 3,000 steps/day from baseline, as indicated in light blue.
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week (cycle ergometers, treadmills). They demonstrated a
13.9% reduction in cfPWV in the intervention arm com-
pared with a 4.4% increase in the control arm (i.e., an
18.3% difference). To be conservative, we aim to detect a
10% difference between our active and control trial arms
to an accuracy of ± 5% over a one-year period. This im-
plies that our CI for the difference will be narrow enough
to rule out only trivial effects. Based on the report by
Madden and colleagues, we estimate a standard deviation
(SD) of 28 in the active treatment arm [standard error, SE*
sqrt (n) = 6.7 * sqrt(17)] and 14 for the control arm
[3.3*sqrt (17)]. Under these conditions, with ± 5% CI
width, we will need to retain 151 per arm (i.e., 302 in
total). Allowing for a loss to follow-up of up to 17% based
on our previous studies, [50,51] we require a sample size
of 364 individuals (i.e., 182 per arm).
Statistical analysis
Our main outcome is percentage change in arterial stiff-
ness (i.e., cfPWV) within each trial arm. We will calculate
mean between trial arm differences in “after minus before
changes”, with 95% CIs (intent-to-treat analysis). In
addition to examining between trial arm differences in
percentage change from baseline arterial stiffness, we will
also evaluate between arm absolute differences in raw
“after minus before changes” in cfPWV. Although trial
arms are likely to be similar at baseline, we may use a lin-
ear model to adjust for any possible differences between
arms for important covariates (e.g., baseline daily steps,
baseline BMI, age, sex, changes in medications). If rele-
vant, in a sensitivity analysis, we will use multiple imput-
ation to impute missing data. A similar approach will be
used to examine between-arm differences in daily steps
and vascular risk factors. We will also correlate incre-
ments in steps to changes in arterial stiffness, anthropo-
metric parameters, and specific vascular risk factors.
Finally, we may employ additional secondary analyses
(e.g., per protocol analyses; analyses in DM2 alone, hyper-
tension alone, DM2 and hypertension; analyses in partici-
pants with and without medication changes).Discussion
The SMARTER trial is testing an innovative step count
prescription strategy delivered by physicians to their pa-
tients with DM2 or hypertension. The focus on daily
step counts arguably simplifies the process of physical
activity prescription. Increasingly, physicians and pa-
tients are partners in monitoring and managing chronic
diseases. Such partnerships can improve patient adhe-
rence and health outcomes [15]. Less than one third
of North Americans achieve the recommended 10,000
steps/day [52] and we have demonstrated that in adults
with DM2 and/or hypertension, mean counts are low at
approximately 5,000 steps/day, with a further 15% reduc-
tion during fall and winter months [50]. “Re-engineering”
walking into daily life could be an effective means of im-
proving the arterial health of patients with DM2 and/or
hypertension.
The effects of the SMARTER intervention are being
determined in terms of biological impact, particularly in
terms of changes in arterial stiffness as captured by
cfPWV. In the Framingham Heart Study, a one SD incre-
ment in arterial stiffness was associated with a 48% in-
crease in arterial disease risk, independently of individual
vascular risk factors [23]. A meta-analysis indicates that
an increase in cfPWV by 1 m/s corresponds to an age-,
sex-, and risk factor-adjusted risk increases of 14%, 15%,
and 15% in total cardiovascular disease event rates, cardio-
vascular mortality, and all cause mortality, respectively
[53]. A recent analysis of the Framingham Offspring study
demonstrated that higher aortic stiffness is associated with
higher risk of incident hypertension [24], suggesting that
in some cases stiffness precedes the development of hy-
pertension. Illustrating the responsiveness of cfPWV to
higher activity levels, a trial among older patients with
vascular risk factors including DM2 demonstrated a
3-month supervised exercise program to confer an im-
portant reduction in cfPWV compared to usual care alone
[25].
We are aware of some potential limitations to the trial.
Firstly, physicians cannot be blinded to the intervention
given that they are delivering it. However, outcome
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both the primary outcome and most of the secondary
outcomes are evaluated objectively (i.e., assays or auto-
mated measurements). We acknowledge the possibility
of contamination of the control arm: that is, physicians
may be tempted to employ the SMARTER intervention
in the control arm, particularly if they perceive benefit.
However, only the active trial arm receives pedometers
at the onset of the intervention period. Following the
final trial evaluation, the control trial arm participants
will be provided with a pedometer in gratitude for their
participation, and they will be free to engage in a step
count prescription strategy with their treating doctor.
This ‘delayed’ intervention may facilitate adherence to
study procedures. Physicians are free to modify medica-
tions during the trial period and this could impact some
outcomes. To address this possibility, we will perform sec-
ondary analyses with (i) adjustment for changes in medi-
cations and (ii) restriction to participants without such
changes. We acknowledge that more frequent contact
with physicians and/or other health care team members
could strengthen the impact of the intervention; however,
DM2 and hypertension follow-up frequently occurs in
settings without multidisciplinary teams and the demands
of clinical care may render more frequent contact chal-
lenging. We have, therefore, designed our intervention to
be ‘pragmatic’ with 3 to 4 follow-up visits over one year
accompanied by a written prescription. Patients with
DM2 and hypertension generally have common features
including insulin resistance and increased risk for vascular
disease. The inclusion of participants with DM2 and
hypertension, each alone or in combination, allows us to
achieve recruitment targets in a reasonable time frame
and to generalize our results to groups of patients seen
frequently in clinical practice; we will nonetheless perform
subgroup analyses (DM2 alone, hypertension alone, DM2
and hypertension in combination).
We have developed our trial in collaboration with phy-
sicians who manage DM2 and hypertension. We held
several meetings with over 24 physicians to discuss the
intervention. They underscored their need for physical
activity promotion tools and viewed the SMARTER
strategy to be feasible and easily integrated into clinical
practice. They, nonetheless, expressed the need for Level
A evidence as derived through a randomized controlled
trial. This integrated knowledge translation approach
will facilitate future knowledge translation efforts. If
effectiveness is demonstrated, we are well-positioned to
consider inclusion in Clinical Practice Recommendations
for DM2 and hypertension.
The SMARTER intervention is novel in several respects:
(i) It is physician-specific intervention that may be par-
ticularly important in understaffed clinics without the sup-
port of a full multidisciplinary team. (ii) A specific, signed,stamped written prescription is provided, focusing on step
count targets. (iii) The rate of step count titration is indi-
vidualized, based on baseline step counts, leveraging an
existing therapeutic alliance. (iv) The primary outcome is
change in arterial stiffness, a summative indicator of arte-
rial health. Prior pedometer-based intervention studies
have examined specific individual vascular risk factors but
to our knowledge, none have evaluated a summative indi-
cator of arterial health (arterial stiffness) as the primary
outcome. (v) A shortcoming of prior studies has often
been a lack of attention to medication use. This is being
carefully recorded during our trial and we will perform
subgroup analyses in those with and without medication
changes (e.g., antihypertensive agents, antihyperglycemic
agents, lipid-lowering agents). We will further evaluate
changes in medication use as a secondary outcome.
(vi) This will be one of the largest pedometer intervention
trials ever conducted (364 participants).
In summary, the potential impact of the SMARTER
intervention relates not only to the use of pedometers
but rather to its incorporation into clinical care, lever-
aging the physician-patient therapeutic alliance. A key
strength of the SMARTER trial is the ability to capture
biological impact through measurement of arterial stiff-
ness. Demonstration of effectiveness of the SMARTER
intervention has strong potential to lead to wide and
sustained adoption in clinical practice with integration
in DM2 and hypertension management.
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